ARQTライブシグナル | Getagraph.comで利益を最大化

買う 25933 min ago

@ $12.30

発行日: 12 4月 2024 @ 01:30

リターン: -28.54%

前回のシグナル: 4月 11 - 23:25

前回のシグナル: 売る

リターン: -0.89 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:43):

Stats
本日の出来高	942 572
平均出来高	4.19M
時価総額	1.01B
EPS	$0 ( 2024-02-27 )
次の収益日	( $-0.650 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.33
ATR14	$0.0160 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Topper David Joseph	Buy	310 000	Stock Option (right to buy)
2024-04-10	Topper David Joseph	Buy	110 000	Common Stock
2024-04-10	Topper David Joseph	Sell	7 500	Stock Option (right to buy)
2024-03-04	Matsuda Masaru	Sell	3 760	Common Stock
2024-03-04	Burnett Patrick	Sell	4 782	Common Stock

INSIDER POWER
30.75
Last 98 transactions
Buy: 3 267 821 \| Sell: 1 662 580

ボリューム相関

長: 0.14 (neutral)

短: 0.51 (weak)

Signal:(59.973) Neutral

Arcutis Biotherapeutics 相関

10 最も正の相関
RCKY	0.919
MORN	0.915
WBA	0.911
CPTN	0.907
CSSE	0.905
PENN	0.903
CNSL	0.902
ENNV	0.901
CSTE	0.898
NYMT	0.897

10 最も負の相関
OBT	-0.916
PRGS	-0.915
HTBI	-0.914
NWPX	-0.911
KTCC	-0.909
VC	-0.907
HUBG	-0.897
JBSS	-0.889
WSC	-0.889
PRN	-0.886

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Arcutis Biotherapeutics 相関 - 通貨/商品

0.33
( neutral )

0.37
( neutral )

0.00
( neutral )

0.67
( moderate )

0.73
( moderate )

-0.64
( weak negative )

Arcutis Biotherapeutics 財務諸表

Annual	2023
収益:	$59.61M
総利益:	$53.49M (89.74 %)
EPS:	$-3.78

FY	2023
収益:	$59.61M
総利益:	$53.49M (89.74 %)
EPS:	$-3.78

FY	2022
収益:	$3.69M
総利益:	$2.93M (79.54 %)
EPS:	$-5.84

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-5.79

Financial Reports:

No articles found.

Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.